Montelukast (MNK) has prominent anti-inflammatory and antioxidant activities. It can
protect the liver in different hepatotoxic models in animals. Simvastatin (SMV) is one of
commonly used lipid lowering drugs for treatment of dyslipidemia in order to reduce cardiovascular
disease. It has severe side effects such as myopathy and hepatotoxicity. The
aim of the present study is to investigate the possible effect of MNK on SMV-induced
myopathy and hepatotoxicity. Four groups of male rats: control group which received
saline via stomach tube, MNK treated group (received 10 mg/kg/day MNK via stomach
tube), SMV treated group (received 30 mg/kg/day SMV via stomach tube), and MNK
+ SMV (combination) group which received both MNK and SMV. All animals were
treated for 14 days before obtaining blood and tissue samples. SMV has both hepatotoxic
effects and myopathy. SMV caused a significant increase in myoglobin, creatinine
kinase, ALT, AST, ALP, and bilirubin but, it decreased total proteins, globulin and albumin
levels. Co-treatment of SMV and MNK increased the antioxidant activity significantly.
MNK modifies partially the myopathic changes and hepatotoxic effect of SMV.
Co-administration of MNK and SMV decreased their toxic potentials on the liver,
skeletal muscles, and kidney. They have antioxidant activities when given together that
producemuscle and hepatic protective effects.